Altered Hippocampal and Striatal Expression of Endothelial Markers and VIP/PACAP Neuropeptides in a Mouse Model of Systemic Lupus Erythematosus

Neuropsychiatric systemic lupus erythematosus (NPSLE) is one of the most common and severe manifestations of lupus; however, its pathogenesis is still poorly understood. While there is sparse evidence suggesting that the ongoing autoimmunity may trigger pathogenic changes to the central nervous system (CNS) microvasculature, culminating in inflammatory/ischemic damage, further evidence is still needed. In this study, we used the spontaneous mouse model of SLE (NZBWF1 mice) to investigate the expression of genes and proteins associated with endothelial (dys)function: tissue and urokinase plasminogen activators (tPA and uPA), intercellular and vascular adhesion molecules 1 (ICAM-1 and VCAM-1), brain derived neurotrophic factor (BDNF), endothelial nitric oxide synthase (eNOS) and Krüppel-like factor 4 (KLF4) and neuroprotection/immune modulation: pituitary adenylate cyclase-activating peptide (PACAP), vasoactive intestinal peptide (VIP), PACAP receptor (PAC1), VIP receptors 1 and 2 (VPAC1 and VPAC2). Analyses were carried out both in the hippocampus and striatum of SLE mice of two different age groups (2 and 7 months old), since age correlates with disease severity. In the hippocampus, we identified a gene/protein expression profile indicative of mild endothelial dysfunction, which increased in severity in aged SLE mice. These alterations were paralleled by moderate alterations in the expression of VIP, PACAP and related receptors. In contrast, we report a robust upregulation of endothelial activation markers in the striatum of both young and aged mice, concurrent with significant induction of the VIP/PACAP system. These data identify molecular signatures of endothelial alterations in the hippocampus and striatum of NZBWF1 mice, which are accompanied by a heightened expression of endogenous protective/immune-modulatory neuropeptides. Collectively, our results support the idea that NPSLE may cause alterations of the CNS micro-vascular compartment that cannot be effectively counteracted by the endogenous activity of the neuropeptides PACAP and VIP.

[1]  J. Hannibal,et al.  Localization of the neuropeptides pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal peptide, and their receptors in the basal brain blood vessels and trigeminal ganglion of the mouse CNS; an immunohistochemical study , 2022, Frontiers in Neuroanatomy.

[2]  Erik W Anderson,et al.  Cognitive dysfunction in SLE: An understudied clinical manifestation. , 2022, Journal of autoimmunity.

[3]  Qian Wang,et al.  Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus , 2022, Journal of clinical medicine.

[4]  F. Napolitano,et al.  Role of Plasminogen Activation System in Platelet Pathophysiology: Emerging Concepts for Translational Applications , 2022, International journal of molecular sciences.

[5]  A. Swarnkar,et al.  Striatal dominant lupus encephalitis–Is it vasculitis or an autoimmune process? Literature review & new case report with vessel wall imaging , 2022, Radiology case reports.

[6]  A. Castorina,et al.  Targeting the neurological comorbidities of multiple sclerosis: the beneficial effects of VIP and PACAP neuropeptides. , 2022, Journal of integrative neuroscience.

[7]  K. Keay,et al.  Metformin Treatment Attenuates Brain Inflammation and Rescues PACAP/VIP Neuropeptide Alterations in Mice Fed a High-Fat Diet , 2021, International journal of molecular sciences.

[8]  C. Putterman,et al.  TWEAKing the Hippocampus: The Effects of TWEAK on the Genomic Fabric of the Hippocampus in a Neuropsychiatric Lupus Mouse Model , 2021, Genes.

[9]  W. Brinjikji,et al.  Striatal Encephalitis: Potential Inflammatory Vasculopathy in Systemic Lupus Erythematosus , 2020, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[10]  Shanshan Liu,et al.  Prevalence, outcome and prognostic factors of neuropsychiatric systemic lupus erythematosus: A real world single center study , 2020, Modern rheumatology.

[11]  Justin G. Roy,et al.  Reliable reference genes for the quantification of mRNA in human T-cells and PBMCs stimulated with live influenza virus , 2020, BMC Immunology.

[12]  Chih-Ming Lin,et al.  A challenging case of neuropsychiatric systematic lupus erythematosus with recurrent antiphospholipid- related stroke: A case report and literature review , 2019, Neurology international.

[13]  Yi Zhu,et al.  BDNF-mediated mitophagy alleviates high-glucose-induced brain microvascular endothelial cell injury , 2019, Apoptosis.

[14]  K. Keay,et al.  PACAP and VIP expression in the periaqueductal grey of the rat following sciatic nerve constriction injury , 2019, Neuropeptides.

[15]  C. Putterman,et al.  Neuropsychiatric lupus: new mechanistic insights and future treatment directions , 2019, Nature Reviews Rheumatology.

[16]  B. Griffith,et al.  Neuropsychiatric Lupus with Antibody-Mediated Striatal Encephalitis , 2018, American Journal of Neuroradiology.

[17]  Y. Joo,et al.  Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study , 2018, Lupus.

[18]  T. Hirabayashi,et al.  Discovery of PACAP and its receptors in the brain , 2018, The Journal of Headache and Pain.

[19]  M. R. Kim,et al.  Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer , 2018, International journal of molecular sciences.

[20]  R. Jenkins,et al.  Markers and Biomarkers of Endothelium: When Something Is Rotten in the State , 2017, Oxidative medicine and cellular longevity.

[21]  Di Lian,et al.  Brain-derived neurotrophic factor reduces inflammation and hippocampal apoptosis in experimental Streptococcus pneumoniae meningitis , 2017, Journal of Neuroinflammation.

[22]  V. Yang,et al.  Krüppel-like factor 4 (KLF4): What we currently know. , 2017, Gene.

[23]  H. Jo,et al.  KLF2 and KLF4 control endothelial identity and vascular integrity. , 2017, JCI insight.

[24]  Lingyun Sun,et al.  Prognosis for Hospitalized Patients with Systemic Lupus Erythematosus in China: 5-Year Update of the Jiangsu Cohort , 2016, PloS one.

[25]  E. Kowalczyk,et al.  Neuroleptic Drugs and PACAP Differentially Affect the mRNA Expression of Genes Encoding PAC1/VPAC Type Receptors , 2016, Neurochemical Research.

[26]  P. Garnier,et al.  Brain BDNF levels are dependent on cerebrovascular endothelium‐derived nitric oxide , 2016, The European journal of neuroscience.

[27]  A. Clarke,et al.  The global burden of SLE: prevalence, health disparities and socioeconomic impact , 2016, Nature Reviews Rheumatology.

[28]  W. Luo,et al.  Role of vasoactive intestinal peptide in osteoarthritis , 2016, Journal of Biomedical Science.

[29]  P. Jayaraman,et al.  Urokinase-type Plasminogen Activator (uPA) Promotes Angiogenesis by Attenuating Proline-rich Homeodomain Protein (PRH) Transcription Factor Activity and De-repressing Vascular Endothelial Growth Factor (VEGF) Receptor Expression* , 2016, The Journal of Biological Chemistry.

[30]  R. Schmidt-Kastner,et al.  Genomic approach to selective vulnerability of the hippocampus in brain ischemia–hypoxia , 2015, Neuroscience.

[31]  A. Rodriguez-Mateos,et al.  Central role of eNOS in the maintenance of endothelial homeostasis. , 2015, Antioxidants & redox signaling.

[32]  J. Waschek,et al.  VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses , 2015, Brain, Behavior, and Immunity.

[33]  D. Ganea,et al.  The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases , 2015, Acta physiologica.

[34]  S. Small,et al.  Isolating Pathogenic Mechanisms Embedded within the Hippocampal Circuit through Regional Vulnerability , 2014, Neuron.

[35]  M. Chopp,et al.  Subacute Intranasal Administration of Tissue Plasminogen Activator Promotes Neuroplasticity and Improves Functional Recovery following Traumatic Brain Injury in Rats , 2014, PloS one.

[36]  Ling Lin,et al.  Tissue plasminogen activator and inflammation: from phenotype to signaling mechanisms. , 2014, American journal of clinical and experimental immunology.

[37]  Shi-ting Li,et al.  Endothelial Nitric Oxide Synthase Protects Neurons against Ischemic Injury through Regulation of Brain‐Derived Neurotrophic Factor Expression , 2014, CNS neuroscience & therapeutics.

[38]  S. Cessie,et al.  Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE) , 2014, Lupus.

[39]  S. Scuderi,et al.  Dopamine D3 receptor deletion increases tissue plasminogen activator (tPA) activity in prefrontal cortex and hippocampus , 2013, Neuroscience.

[40]  Abdullah M. Khamis,et al.  Regional differences in gene expression and promoter usage in aged human brains , 2013, Neurobiology of Aging.

[41]  H. Ueda,et al.  Epigenetic regulation of BDNF expression in the primary sensory neurons after peripheral nerve injury: Implications in the development of neuropathic pain , 2013, Neuroscience.

[42]  S. Bilbo,et al.  Chemokines and the hippocampus: A new perspective on hippocampal plasticity and vulnerability , 2013, Brain, Behavior, and Immunity.

[43]  B. Tzang,et al.  Cystamine ameliorates ventricular hypertrophy associated with modulation of IL-6-mediated signaling in lupus-prone mice. , 2013, Life sciences.

[44]  Gai-feng Feng,et al.  Vasoactive intestinal peptide increases VEGF expression to promote proliferation of brain vascular endothelial cells via the cAMP/PKA pathway after ischemic insult in vitro , 2013, Peptides.

[45]  R. Carare,et al.  Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid‐β from the mouse brain , 2013, Aging cell.

[46]  M. Mao,et al.  The neuroprotective roles of BDNF in hypoxic ischemic brain injury. , 2013, Biomedical reports.

[47]  C. Qualls,et al.  Circulating microparticles in neuropsychiatric systemic lupus erythematosus , 2013, International journal of rheumatic diseases.

[48]  C. Putterman,et al.  Neuropsychiatric Symptoms in Lupus. , 2012, Psychiatric annals.

[49]  U. Förstermann,et al.  Nitric oxide synthases: regulation and function. , 2012, European heart journal.

[50]  Olga Hilas,et al.  Lupus: an overview of the disease and management options. , 2012, P & T : a peer-reviewed journal for formulary management.

[51]  F. Drago,et al.  Dopamine-₃ receptor modulates intraocular pressure: implications for glaucoma. , 2012, Biochemical pharmacology.

[52]  A. Popescu,et al.  Neuropsychiatric Systemic Lupus Erythematosus , 2011, Current neuropharmacology.

[53]  V. Cardile,et al.  Effects of PACAP and VIP on hyperglycemia-induced proliferation in murine microvascular endothelial cells , 2010, Peptides.

[54]  B. Hart,et al.  Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. , 2010, Seminars in arthritis and rheumatism.

[55]  E. Muscal,et al.  Neurologic manifestations of systemic lupus erythematosus in children and adults. , 2010, Neurologic clinics.

[56]  H. Vaudry,et al.  Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery , 2009, Pharmacological Reviews.

[57]  R. Eisenberg Why can't we find a new treatment for SLE? , 2009, Journal of autoimmunity.

[58]  M. Lisanti,et al.  ICAM-1: role in inflammation and in the regulation of vascular permeability. , 2008, American journal of physiology. Heart and circulatory physiology.

[59]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[60]  Petti T. Pang,et al.  Cleavage of proBDNF by tPA/Plasmin Is Essential for Long-Term Hippocampal Plasticity , 2004, Science.

[61]  A. Bobik,et al.  Metalloproteinases and plasminogen activators in vessel remodeling , 2003, Current hypertension reports.

[62]  C. Lau,et al.  Pathogenesis of systemic lupus erythematosus , 2003, Journal of clinical pathology.

[63]  P. Rieckmann,et al.  Human cerebral endothelial cells are a potential source for bioactive BDNF. , 2002, Cytokine.

[64]  M. Delgado,et al.  Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[65]  R. Schmidt-Kastner,et al.  Selective vulnerability of the hippocampus in brain ischemia , 1991, Neuroscience.

[66]  M. van Buchem,et al.  Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement , 2017, Rheumatology.

[67]  Kyuhyung Kim,et al.  Neuropeptides. , 2008, WormBook : the online review of C. elegans biology.

[68]  P. Cieślik,et al.  Vasculopathy and vasculitis in systemic lupus erythematosus. , 2008, Polskie Archiwum Medycyny Wewnetrznej.

[69]  M. Delgado,et al.  Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases , 2001, Journal of Molecular Medicine.